ZENITH-CKD is the first randomized trial comparing combined SGLT2 and endothelin A inhibition in patients with chronic kidney disease. Endothelin system blockade with zibotentan is a potential new therapy in chronic kidney disease (CKD).
ZENITH-CKD is the first randomized trial comparing combined SGLT2 and endothelin A inhibition in patients with chronic kidney disease. Endothelin system blockade with zibotentan is a potential new therapy in chronic kidney disease (CKD).
The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2023 November 1–November 5.
Zibotentan/Dapagliflozin Mix Cuts Albuminuria in ZENITH-CKD Trial miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.